This company has been marked as potentially delisted and may not be actively trading. Spark Therapeutics (ONCE) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock Spark Therapeutics Short Interest DataSpark Therapeutics (ONCE) has a short interest of 3.47 million shares, representing 9.97% of the float (the number of shares available for trading by the public). This marks a -1.98% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.5, indicating that it would take 6.5 days of the average trading volume of 891,560 shares to cover all short positions.Current Short Interest3,470,000 sharesPrevious Short Interest3,540,000 sharesChange Vs. Previous Month-1.98%Dollar Volume Sold Short$386.00 millionShort Interest Ratio6.5 Days to CoverLast Record DateNovember 29, 2019Outstanding Shares38,523,000 sharesFloat Size34,800,000 sharesShort Percent of Float9.97%Today's Trading Volume0 sharesAverage Trading Volume891,560 sharesToday's Volume Vs. Average0% Short Selling Spark Therapeutics? Sign up to receive the latest short interest report for Spark Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Spark Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date ONCE Short Interest - Frequently Asked Questions What is Spark Therapeutics' current short interest? Short interest is the volume of Spark Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 29th, investors have sold 3,470,000 shares of ONCE short. 9.97% of Spark Therapeutics' shares are currently sold short. Learn More on Spark Therapeutics' current short interest. What is a good short interest ratio for Spark Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ONCE shares currently have a short interest ratio of 6.0. Learn More on Spark Therapeutics's short interest ratio. What is a good short interest percentage for Spark Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.97% of Spark Therapeutics' floating shares are currently sold short. Is Spark Therapeutics' short interest increasing or decreasing? Spark Therapeutics saw a decline in short interest during the month of November. As of November 29th, there was short interest totaling 3,470,000 shares, a decline of 2.0% from the previous total of 3,540,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Spark Therapeutics' float size? Spark Therapeutics currently has issued a total of 38,523,000 shares. Some of Spark Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Spark Therapeutics currently has a public float of 34,800,000 shares. How does Spark Therapeutics' short interest compare to its competitors? 9.97% of Spark Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Spark Therapeutics: Cyclo Therapeutics, Inc. (3.55%), Cognition Therapeutics, Inc. (1.82%), Elevation Oncology, Inc. (16.57%), Passage Bio, Inc. (3.47%), BioAtla, Inc. (9.49%), IN8bio, Inc. (0.74%), SAB Biotherapeutics, Inc. (0.95%), Curis, Inc. (2.31%), Athira Pharma, Inc. (2.45%), BioCardia, Inc. (1.08%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Slack Technologies, Inc. ($887.06 million), CrowdStrike Holdings, Inc. ($441.98 million), Spark Therapeutics Inc ($386.00 million), Carrizo Oil & Gas, Inc. ($169.28 million), Rocket Pharmaceuticals, Inc. ($153.59 million), CEL-SCI Co. ($51.42 million), Presidio Inc ($39.72 million), Vitamin Shoppe Inc ($22.16 million), Anavex Life Sciences Corp. ($14.63 million), and Affimed ($11.43 million). View all of the most shorted stocks. What does it mean to sell short Spark Therapeutics stock? Short selling ONCE is an investing strategy that aims to generate trading profit from Spark Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Spark Therapeutics? A short squeeze for Spark Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ONCE, which in turn drives the price of the stock up even further. How often is Spark Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ONCE, twice per month. The most recent reporting period available is November, 29 2019. More Short Interest Resources from MarketBeat Related Companies CYTH Short Interest Data CGTX Short Interest Data ELEV Short Interest Data PASG Short Interest Data BCAB Short Interest Data INAB Short Interest Data SABS Short Interest Data CRIS Short Interest Data ATHA Short Interest Data BCDA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ONCE) was last updated on 4/28/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spark Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Spark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.